Nucala is a medication aligned to the HCPCS J Code: J2182 for billing, pricing, and reimbursement purposes in the United States. It is an Anti-Eosinophil Asthma drug administered via the subcutaneous route and manufactured by multiple companies.
According to CMS Drug Use Information: This medication is used along with other medications to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD). Controlling symptoms of breathing problems helps you do your normal activities and decreases time lost from work or school. Mepolizumab is also used to treat certain other immune system disorders (chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome). This medication works by decreasing a certain type of white blood cell (eosinophils). This effect helps reduce swelling (inflammation) of the airways to make breathing easier. It may also help reduce the size of nasal polyps, and lessen symptoms such as runny/stuffy nose, mucus in the throat, loss of smell, facial pain, and tiredness. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks or breathing problems. If sudden breathing problems occur, use your quick-relief inhaler as prescribed.
Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.
